Private Companies 4

UK

October 17, 2017: Cambridge Enterprise Limited issued new U.S. patent [9,790,470]

NEWS BITES - PRIVATE COMPANIES

Cambridge Enterprise Limited has been issued a new U.S. patent titled "In vitro pancreatic differentiation of pluripotent mammalian cells" by the US Patent and Trademark Office.

ABSTRACT

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor (FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3.beta. inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.

Appl. No.14/429,869
PCT FiledSeptember 16, 2013
PCT No.PCT/EP2013/069188

INDEX

SECTION 1 CAMBRIDGE ENTERPRISE LIMITED FINANCIALS

SECTION 2 CAMBRIDGE ENTERPRISE LIMITED PROFILE

SECTION 3 OTHER NEWS: 2015

SECTION 4 OTHER NEWS: 2014

SECTION 5 CAMBRIDGE ENTERPRISE LIMITED PATENTS

SECTION 6 CAMBRIDGE ENTERPRISE LIMITED TOP MANAGEMENT

SECTION 1 CAMBRIDGE ENTERPRISE LIMITED FINANCIALS

FY2016 Annual Report: Cambridge Enterprise Limited profits hit by 33.8% fall

Major changes compared with previous year:

Favourable Changes:

Cost of Goods Sold to Sales down from 71% to 59%

Sales and marketing expenses to Sales down from 59% to 34%

Fixed Assets to Total Assets up from 47% to 50%

Total non-current assets to Total Assets up from 47% to 50%

Unfavourable Changes:

Net profit slumps 34% from GBP3.4m ($US5.3m) to GBP2.3m ($US3.0m)

Total liabilities to Total assets up 53% from 0.3 to 0.5

Current ratio down 42% from 1.8 to 1.0

Working capital to total assets down from 23.7% to 1.9%

Total current assets to Total Assets down from 53% to 50%

Cash to Total Assets down from 32% to 24%

Note:

Total revenue to total assets steady at 0.4

Annual

Company Name : Cambridge Enterprise Limited
July 312016201520162015Change
DescriptionGBP ('000)GBP ('000)$US ('000)$US ('000)(%)
Sales Revenue8,7895,35011,6458,332Up 64
Depreciation24203232Up 17
Profit/(Loss) after Tax2,2643,4192,9995,324Slumps 34
Working Capital3793,9275026,116Down 90
Current Assets10,1608,82313,46113,741Up 15
Current Liabilities9,7814,89612,9597,625Up 100
Shareholders' Funds9,70510,99412,85817,121Down 12
Total Liabilities10,4725,55513,8748,651Up 89
Total Assets20,17716,54926,73125,773Up 22
Non-Current Debt6916599151,026Up 5
Total Debt6979269241,442Down 25
Cash and cash equivalents4,7905,3066,3468,263Down 10
AuditorPRICEWATERHOUSECOOPERS LLP  

July 3120162015Change (%)
Performance Ratios
Return on Equity (%)2331Down 25
Return on Assets (%)1121Down 46
Common Size Ratios by Assets %
Total current assets to Total Assets 50.4 53.3 Down 5.5
Fixed Assets to Total Assets 49.6 46.7 Up 6.2
Total non-current assets to Total Assets 49.6 46.7 Up 6.2
Cash to Total Assets 23.7 32.1 Down 26.1
Common Size Ratios by Sales %
Cost of Goods Sold to Sales 58.6 71.1 Down 17.5
Sales and marketing expenses to Sales 33.9 58.6 Down 42.2
Depreciation to Sales 0.3 0.4 Down 21.3
Interest expenses to Sales 0.2 0.1 Up 41.9

Currency Conversion (July 31, 2016): $US1 = GBP0.75

Currency Conversion (July 31, 2015): $US1 = GBP0.64

SECTION 2 CAMBRIDGE ENTERPRISE LIMITED PROFILE

2.1 ACTIVITIES

Cambridge Enterprise Limited provides technology transfer and consultancy services. Its technology transfer services include disclosure management, proof of concept funding, research reagents transfer, and intellectual property licensing and bespoke marketing; and patent strategy, filing, and maintenance. The companys consultancy services comprise negotiation of contract terms, assistance with costing and pricing, formal arrangements for use of University facilities, invoicing, debt collection, and income distribution. It also offers pre-seed and seed stage investment for members of the University of Cambridge and the Babraham Institute, to help commercialize innovative research through the creation of new ventures. In addition, it works with University inventors to license patentable ideas to new and existing companies. The company serves university and industry customers. Cambridge Enterprise Limited was formerly known as Cambridge University Technical Services Limited and changed its name to Cambridge Enterprise Limited in November 2006. The company was incorporated in 1972 and is based in Cambridge, United Kingdom. Cambridge Enterprise Limited is a subsidiary of University of Cambridge.

2.2 SUMMARY

Fiscal Year End: 31 Jul 2016

PermID: 5035525035

Website: http://www.enterprise.cam.ac.uk

SECTION 3 OTHER NEWS: 2015

March 19: Cambridge Enterprise Limited: University spin-out XO1 acquired by Janssen

[Company Release]

University of Cambridge spin-out XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab, has been acquired by Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Financial terms of the transaction have not been disclosed.

"We are delighted that Janssen Pharmaceuticals will now be investing further in this programme." - Dr. Andrew Walsh, Cambridge Enterprise

Ichorcumab is a recombinant human antibody developed to mimic the activity of a human antibody that appears to produce an anticoagulated state without predisposition to bleeding. The drug was initially developed by Cambridge University Hospitals and Cambridge University with support from Cambridge Enterprise, the University's commercialisation arm.

The technology was licensed by Cambridge Enterprise to XO1 Limited in order to take its development towards the clinic. XO1 Limited was established by Index Ventures as an asset centric company, a model advanced by Index, via a fund launched in 2012 in which Johnson & Johnson Innovation - JJDC, Inc. is an investor.

"XO1 has made great progress with Ichorcumab," said Dr. Andrew Walsh, a technology manager at Cambridge Enterprise.

January 12: Cambridge Enterprise Limited: Fluidic Analytics secures Pound1.56 million to develop new protein characterisation technology

[Company Release] Fluidic Analytics Limited, a spin-out from the University of Cambridge, has raised Pound1.56 million (US$2.4 million) in a Series A financing led by Cambridge Enterprise and including DFJ Esprit, IQ Capital, Parkwalk Advisors and Amadeus Capital Partners as co-investors.

"Fluidic Analytics perfectly illustrates how a University of Cambridge spin-out supported by Cambridge Enterprise can merge the work of academics, entrepreneurs and early stage investors to bring potentially world-changing technology to market." - Bradley Hardiman, Investment Manager at Cambridge Enterprise

Fluidic Analytics has developed a proprietary technology to characterise proteins in a rapid, accurate and cost-effective manner. The technology is based on research conducted at the University of Cambridge and has high-value applications including identifying markers that indicate the onset of diseases in the human body.

In contrast to DNA, whose sequence provides information on the likelihood of developing a disease at some point in life, proteins provide real-time information on the actual, current disease state of the body. Real-time information on disease states is widely seen as the key to timely, effective medical treatment.

SECTION 4 OTHER NEWS: 2014

October 31: Cambridge Epigenetix raises $5.5M in Series A funding

[Company Release]

CEGX is a rapidly growing company focused on developing innovative methods and technologies to revolutionize the fields of epigenetics and personalized medicine. The company was founded in 2012 with its proprietary ox-BS methodology, which pioneered quantitative, single-base resolution sequencing of 5-hydroxymethylcytosine (5hmC) & 5-methylcytosine (5mC). In 2013, CEGX launched the TrueMethyl(TradeMark) kit, allowing researchers to access ox-BS sequencing for the first time. The TrueMethyl(TradeMark) kit is now in use in labs around the world and has already formed the technological backbone of several breakthrough epigenetic papers.

"Cambridge Epigenetix has received considerable attention from the investment community over the past year, and we are delighted to welcome New Science Ventures to the board," said Dr. Martin Murphy, CEO of Syncona Partners and Chairman of the Board at CEGX. He added: "We would also like to welcome our new CEO, Dr. Fedja Bobanovic, who has an exceptional track record of generating growth in life sciences businesses."

Commenting on the financing, Dr. Bobanovic, who joined CEGX from Danaher Corp. said, "Cambridge Epigenetix plans to use the funding to continue to explore a range of commercial applications for our oxBS-sequencing products in the life sciences industry.

October 29: New Cambridge Enterprise office opens on University Biomedical Campus

[Company Release]

Cambridge Enterprise, the University's commercialisation arm, is expanding its reach with the opening of an adjunct office on the first floor of the University's School of Clinical Medicine, providing a base on the Addenbrooke's site for the Cambridge Enterprise Life Sciences team. Cambridge Enterprise is headquartered at the Hauser Forum on the University's West Cambridge Site.

"CE's new permanent office at the centre of the Biomedical Campus highlights the University's and hospitals' on-going and increasing commitment to capitalising on the many exciting innovations developed by clinicians and researchers on the site," said Cambridge Enterprise healthcare manager Andrew Walsh.

Cambridge Enterprise is tasked with assisting members of the University to make their ideas more commercially successful. This is done through the identification and development of commercially valuable intellectual property (IP), the formation of new companies and by supporting the provision of consultancy services to industry. Cambridge Enterprise also supports IP generated by members of Cambridge University Hospitals staff in collaboration with the University.

The new office on the Addenbrooke's site will be manned daily by Walsh, NIHR BRC IP manager Michale Bouskila, and other members of the Cambridge Enterprise Life Sciences team.

September 29: New Cambridge Enterprise office opens on University Biomedical Campus

[Company Release] Cambridge Enterprise, the University's commercialisation arm, is expanding its reach with the opening of an adjunct office on the first floor of the University's School of Clinical Medicine, providing a base on the Addenbrooke's site for the Cambridge Enterprise Life Sciences team. Cambridge Enterprise is headquartered at the Hauser Forum on the University's West Cambridge Site.

"CE's new permanent office at the centre of the Biomedical Campus highlights the University's and hospitals' on-going and increasing commitment to capitalising on the many exciting innovations developed by clinicians and researchers on the site," said Cambridge Enterprise healthcare manger Andrew Walsh.

Cambridge Enterprise is tasked with assisting members of the University to make their ideas more commercially successful. This is done through the identification and development of commercially valuable intellectual property (IP), the formation of new companies and by supporting the provision of consultancy services to industry. Cambridge Enterprise also supports IP generated by members of Cambridge University Hospitals staff in collaboration with the University.

The new office on the Addenbrooke's site will be manned daily by Walsh, NIHR BRC IP manager Michale Bouskila, and other members of the Cambridge Enterprise Life Sciences team.

SECTION 5 CAMBRIDGE ENTERPRISE LIMITED PATENTS

PREVIOUS 10 PATENT STORIES:

Issue DateIssuing OfficePatent TitlePatent Number
Oct 10, 2017US PTOTreatment of diseases related to hyperactivity of the complement system9,782,460
Oct 6, 2017EPOMETHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSISHRP20171023 (T1)
Sep 26, 2017US PTOOptical device and methods9,774,930
Sep 25, 2017EPOMETHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE SECONDARY TO MULTIPLE SCLEROSISLT2344677 (T)
Sep 5, 2017US PTOOrganic semiconductors9,755,151
Aug 9, 2017EPOTransistor DevicesGB2547160 (A)
Aug 1, 2017US PTOFunctional inks based on layered materials and printed layered materials9,718,972
Jul 18, 2017US PTOCoated microfluidic devices and methods of making9,707,557
Jul 11, 2017US PTOThermocouple apparatus and method9,702,764
Jul 11, 2017US PTOMarkers for breast cancer9,702,011

SECTION 6 CAMBRIDGE ENTERPRISE LIMITED TOP MANAGEMENT

Dr Tony Raven, CEO

Dr Tony Raven joined Cambridge Enterprise as Chief Executive in December 2011. Previously he was Director of Research & Innovation Services at the University of Southampton, where he helped establish Southampton's international reputation as a leading entrepreneurial university, creating a portfolio of 11 spin-out companies with four listings on the London Stock Exchange.

After graduating with a First in physics from Manchester University, he obtained his MSc and DPhil from the University of Oxford. He worked at Rutherford Appleton Laboratories and Osaka University before joining Cambridge-based PA Consulting in 1983.

In 1985 he was a founder of Summit Technology, the market leader in laser refractive surgery, which was acquired by Nestle Alcon in 2000 for $893 million. In 1987 he co-founded Cambridge-based Sagentia Group plc, a technical and management consultancy which is listed on the London Stock Exchange. In 1991 he founded Diomed Inc, a pioneer and world leader in therapeutic medical diode lasers, and served as CEO and Deputy Chairman until 2000.

Dr Raven is a Fellow of the Institute of Physics and a Member of the Institute of Directors.

PermID: 5035525035

Created by www.buysellsignals.com for News Bites Finance